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INTRODUCTION 
njection drug use has emerged as a critical concern of judicial and 
public health systems worldwide. Internationally, there are now an 
estimated sixteen million injection drug users (IDU) residing in every 
global hemisphere.1 This population experiences a high degree of 
marginalization and disproportionately high levels of health and 
social harms compared with the general population.2 Of greatest 
 
* School of Population and Public Health, University of British Columbia, Vancouver, 
Canada. 
1 UNITED NATIONS OFFICE ON DRUGS AND CRIME, WORLD DRUG REPORT 2011, at 30 
(2011). 
2 See GLOBAL COMM’N ON DRUG POLICY, THE WAR ON DRUGS AND HIV/AIDS: HOW 
THE CRIMINALIZATION OF DRUG USE FUELS THE GLOBAL PANDEMIC 3 (June 2012) 
[hereinafter GLOBAL COMM’N ON DRUG POLICY, THE WAR ON DRUGS AND HIV/AIDS]; 
I
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concern are heightened rates of mortality among IDU, which result 
primarily from epidemic levels of HIV infection and fatal overdose. 
These twin epidemics of injection drug use and HIV have spurred 
the reevaluation of current illicit drug policies worldwide. Drug 
policy approaches have been remarkably consistent internationally 
since the latter half of the twentieth century, with almost every United 
Nations (UN) member state a party to the three UN Conventions 
related to drug use: the 1961 Single Convention, the 1972 Convention 
on Psychotropic Substances, and the 1988 Convention Against Illicit 
Trafficking.3 The result of this widespread adoption of prohibitive 
drug policies has been that, while the intensity of drug policies varies 
across countries,4 drug law enforcement is almost universally 
employed in an effort to reduce drug use and control drug-related 
harms.5 
While drug law enforcement has been applied in an effort to reduce 
levels of drug use and the size of illicit drug markets, consensus is 
emerging that this approach has resulted in severe public health and 
social costs, including mass incarceration, the extreme social 
marginalization of drug users, and the rapid spread of HIV among 
IDU.6 The evidence also suggests that drug law enforcement has not 
achieved its primary goal: reduction of drug use or supply.7 
 
Dan Werb et al., Vienna Declaration: A Call For Evidence-Based Drug Policies, 376 
LANCET 310, 311 (2010). 
3 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances, opened for signature Dec. 20, 1988, 1582 U.N.T.S. 164, 28 I.L.M. 493; 
Protocol Amending the Single Convention on Narcotic Drugs, 1961, opened for signature 
Mar. 25, 1972, 26 U.S.T. 1439, 976 U.N.T.S. 3; Convention on Psychotropic Substances, 
opened for signature Feb. 21, 1971, 32 U.S.T. 543, 1019 U.N.T.S. 175; Single Convention 
on Narcotic Drugs, opened for signature Mar. 30, 1961, 18 U.S.T. 1407, 520 U.N.T.S. 
151. 
4 Louisa Degenhardt et al., Toward a Global View of Alcohol, Tobacco, Cannabis, and 
Cocaine Use: Findings From the WHO World Mental Health Surveys, 5 PLOS MED. 
1053, 1056 (2008). 
5 INT’L NARCOTICS CONTROL BD, UNITED NATIONS, REPORT OF THE INTERNATIONAL 
NARCOTICS CONTROL BOARD FOR 2010, at 9–12 (2011). 
6 See, e.g., Chris Beyrer et al., Drug Use, Increasing Incarceration Rates, and Prison-
Associated HIV Risks in Thailand, 7 AIDS & BEHAV. 153, 159–60 (2003); Jennifer G. 
Clarke et al., Active and Former Injection Drug Users Report of HIV Risk Behaviors 
During Periods of Incarceration, 22 SUBSTANCE ABUSE 209, 209–10 (2001); Becky Pettit 
& Bruce Western, Mass Imprisonment and the Life Course: Race and Class Inequality in 
U.S. Incarceration, 69 AM. SOC. REV., 151, 164–65 (2004); Amy Rock Wohl et al., High-
Risk Behaviors During Incarceration in African-American Men Treated for HIV at Three 
Los Angeles Public Medical Centers, 24 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES 
386, 387 (2000); Daniel Werb et al., Effects of Police Confiscation of Illicit Drugs and 
Syringes Among Injection Drug Users in Vancouver, 19 INT’L J DRUG POL’Y 332, 335–36 
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As such, this Article examines the scientific evidence on medical 
regulatory frameworks for illicit opioids and suggests an alternative 
drug policy that requires tolerating drug use to lessen the negative 
results of injection drug use, such as HIV epidemics related to the 
injection of illicit substances. Part I reviews the drug enforcement 
policies currently employed to reduce drug use and identifies some 
weaknesses of that approach. Part II describes an alternative drug 
policy through the specific example of heroin-assisted treatment for 
persons addicted to opioids. Part III proposes that the observed 
benefits of heroin-assisted treatment may translate more broadly to a 
new drug policy framework. By tolerating small amounts of drug use 
in heroin-assisted treatment and other clinically proven treatment 
options, policymakers can begin to combat ongoing morbidity and 
mortality arising from untreated drug dependence. 
I 
CURRENT DRUG ENFORCEMENT POLICIES 
The current system of drug law enforcement aims to eliminate drug 
use by reducing the demand for and supply of illicit drugs. To that 
end, supply-side policies have become increasingly marked by drug 
interdiction and anti-trafficking strategies to eradicate the supply of 
illegal drugs in consumer markets such as North America and 
Europe.8 This has included the militarization and internationalization 
of counternarcotics efforts, particularly in export market zones such 
as Latin America, Afghanistan, and Southeast Asia.9 
 
(2008); Pew Ctr. on the States, One in 100: Behind bars in America 2008, at 3–4 (2008), 
http://www.pewtrusts.org/our_work_report_detail.aspx?id=35900. 
7 See Degenhardt, supra note 4, at 1061–65. See generally ARTHUR FRIES ET AL., INST. 
FOR DEF. ANALYSIS, IDA PAPER P-4332, THE PRICE AND PURITY OF ILLICIT DRUGS: 1981 
– 2007 (2008). 
8 EXEC. OFFICE OF THE PRESIDENT, BUDGET AND PERFORMANCE SUMMARY, FISCAL 
YEAR 2012, at 43–44 (Apr. 2011), available at http://www.whitehouse.gov/sites/default 
/files/ondcp/Fact_Sheets/FY2012-Budget-and-Performance-Summary-April-2011.pdf. 
9 See, e.g., CONNIE VEILLETTE, CONG. RESEARCH SERV., PLAN COLOMBIA: A 
PROGRESS REPORT 12 (2005) (Columbia); TOM KRAMER ET AL., TRANSNATIONAL INST., 
WITHDRAWAL SYMPTOMS IN THE GOLDEN TRIANGLE: A DRUGS MARKET IN DISARRAY 
18–19 (Jan. 2009) (Southeast Asia); MINISTRY OF COUNTER NARCOTICS, NATIONAL 
DRUG CONTROL STRATEGY: AN UPDATED FIVE-YEAR STRATEGY FOR TACKLING THE 
ILLICIT DRUG PROBLEM 44 (2006) (Afg.); CORY MOLZAHN ET AL., TRANS-BORDER INST., 
SPECIAL REPORT, DRUG VIOLENCE IN MEXICO: DATA AND ANALYSIS THROUGH 2011, at 
2 (2011) (Mexico); John Hellin, Coca Eradication in the Andes: Lessons from Bolivia, 12 
CAPITALISM NATURE SOCIALISM 151–52 (2001) (Bolivia). 
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With respect to demand-side interventions, drug law enforcement 
is often expressed most intensely at the street level, particularly in 
urban centers within consumer markets.10 These interventions 
generally take the form of police crackdowns on open-air illicit drug 
markets,11 with concomitant high levels of discretionary policing,12 
arrest and incarceration of drug users.13 Despite their aims, however, 
these policies have been largely unsuccessful at minimizing drug 
markets and drug use.14 
As such, policymakers have begun to explore alternatives. In 
particular, the regulation of illicit drugs under a strict public health or 
medical system has been applied in a select number of settings, most 
notably in Western Europe.15 While these systems differ in 
application, evidence suggests that they may be effective in reducing 
certain-drug related harms.16 
There is some evidence to suggest, however, that other—perhaps 
more serious—drug-related harms have emerged as a result of these 
policies. For example, approximately three million IDU are estimated 
 
10 See, e.g., Ernest Drucker, Population Impact of Mass Incarceration Under New 
York’s Rockefeller Drug Laws: An Analysis of Life of Years Lost, 79 J. URB. HEALTH 434, 
441–43 (2002); Samuel R. Friedman et al., Drug Arrests and Injection Drug Deterrence, 
101 AM. J. PUB. HEALTH 344, 344 (2011); Samuel R. Friedman et al., Relationships of 
Deterrence and Law Enforcement to Drug-Related Harms Among Drug Injectors in US 
Metropolitan Areas, 20 AIDS 93, 97 (2006). 
11 See, e.g., JOANNE CSETE & JONATHAN COHEN, HUMAN RIGHTS WATCH, ABUSING 
THE USER: POLICE MISCONDUCT, HARM REDUCTION AND HIV/AIDS IN VANCOUVER 10 
(vol. 15, 2003); Lisa Maher & David Dixon, The Cost of Crackdowns: Policing 
Cabramatta’s Heroin Market, 13 CURRENT ISSUES CRIM. JUST. 5, 5–6 (2001); Michael R. 
Smith, Police-Led Crackdowns and Cleanups: An Evaluation of a Crime Control Initiative 
in Richmond, Virginia, 47 CRIME & DELINQ. 60, 60–61 (2001); Evan Wood et al., 
Displacement of Canada’s Largest Public Illicit Drug Market in Response to a Police 
Crackdown, 170 CANADIAN MED. ASS’N J. 1551, 1551 (2004); Richard S. Ehrlich, 
Thailand’s Drug War Leaves a Bloody Trail; Police Suspected in ‘Extrajudicial Killings’ 
of Dealers, WASH. TIMES (Feb. 21, 2003), http://www.washingtontimes.com/news/2003 
/feb/21/20030221-085615-5997r/. 
12 Maher & Dixon, supra note 11, at 15–16; Werb, supra note 6, at 335–36.  
13 Beyrer et al., supra note 6, at 158; Jonathan P. Caulkins & Sara Chandler, Long-Run 
Trends in Incarceration of Drug Offenders in the United States, 52 CRIME & DELINQ. 619, 
619–20 (2006); Lisa D. Moore & Amy Elkavich, Who’s Using and Who’s Doing Time: 
Incarceration, the War on Drugs, and Public Health, 98 AM. J. PUB. HEALTH 782, 782 
(2008). 
14 See generally FRIES ET AL., supra note 7; Degenhardt et al., supra note 4, at 1054. 
15 See EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION, DRUG 
POLICY PROFILES: PORTUGAL 23–24 (2011) (Port.). 
16 GLENN GREENWALD, CATO INST., DRUG DECRIMINALIZATION IN PORTUGAL: 
LESSONS FOR CREATING FAIR AND SUCCESSFUL DRUG POLICIES 12–16 (2009). 
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to be infected with HIV globally;17 in the Russian Federation, with an 
estimated population of 1.8 million IDU, IDU make up 60% of all 
HIV cases.18 In other settings with large populations of IDU, such as 
China, 38.5% of all HIV-seropositive individuals are IDU, while in 
the United States, approximately 308 thousand of the 1.86 million 
American IDU are believed to be HIV-seropositive.19 
Similarly, levels of fatal overdose among IDU populations are 
unacceptably high. The United Nations Office on Drugs and Crime 
estimates that globally between 99,000 and 253,000 individuals died 
of a drug overdose in 2010.20 In the United States, overdose deaths 
related to heroin and cocaine use rose steadily in the 2000s, with 
approximately 4,500 cocaine-related and 3,000 heroin-related 
overdose deaths reported in 2008.21 Such evidence mandates that 
other metrics, besides supply and demand for illicit drugs, begin to 
guide our drug policy. 
II 
RESPONSES TO OPIOID DEPENDENCE 
The increasing recognition of drug dependence as a chronic, 
treatable condition has led medical professionals to begin 
experimenting with medically-supervised illicit drug prescription as 
an alternative to prohibition-based drug policies. This Part, therefore, 
looks to medical regulation of opioid derivatives and physician-
supervised rehabilitation programs as a model for successful drug 
policy. 
A. Medical Regulation of Opioid Derivatives 
Generally, substances are regulated for medical use if they 
demonstrate utility within a medical context but also exhibit potential 
harms. For instance, morphine is an opioid analgesic used widely in 
medical settings to relieve pain, and it has become an indispensable 
tool of medical practitioners, so much so that it has been placed on the 
 
17 GLOBAL COMM’N ON DRUG POLICY, THE WAR ON DRUGS AND HIV/AIDS, supra 
note 2, at 4. 
18 Chris Beyrer et al., Time to Act: A Call for Comprehensive Responses to HIV in 
People Who Use Drugs, 376 LANCET 551, 554, 560 (2010). 
19 Id. at 560. 
20 UNITED NATIONS OFFICE ON DRUGS AND CRIME, WORLD DRUG REPORT 2012, at 
17. (2012). 
21 Id. at 82. 
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World Health Organization’s List of Essential Medicines.22 However, 
morphine also exhibits highly addictive properties, and its use is thus 
highly restricted within medical contexts such as palliative care, 
surgical recovery, or chronic pain management.23 
Striking a balance between medical use and potential harms 
through regulation is replicated across the spectrum of available 
pharmacotherapies. As a result, the regulation of pharmacotherapies 
evolved considerably over the twentieth century. 
Diacetylmorphine, commonly known as heroin, was originally 
developed in the nineteenth century and later used as a morphine 
substitute and cough suppressant.24 Originally prescribed and 
distributed widely, its potent addictive properties and potential harms 
resulted in a rapid restriction of its application,25 until it was formally 
prohibited in the United States in 1924.26 Since that time, controlling 
the illicit use and supply of heroin has been a central concern of drug 
policies,27 and the development of clinical treatment modalities for 
drug dependence has focused specifically on heroin dependence. 
B. Current Clinical Treatments for Opioid Addiction 
Currently, methadone, along with buprenorphine, represents the 
most widely recommended clinical therapy for opioid dependence.28 
Methadone is used in the context of maintenance therapy, in which 
individuals who are heroin-dependent transition to controlled, 
sustained methadone use, prescribed within a clinical context. This is 
done in recognition of opioid dependence as a chronic, recurring 
 
22 WORLD HEALTH ORG., ESSENTIAL MEDICINES: WHO MODEL LIST 1–2 (13th ed. 
2003). 
23 See K. Suresh Kumar et al., Intravenous Morphine for Emergency Treatment of 
Cancer Pain, 14 PALLIATIVE MED. 183, 184 (2000); Cecilia Sepúlveda et al., Palliative 
Care: The World Health Organization’s Global Perspective, 24 J. PAIN & SYMPTOM 
MGMT 91, 91, 93 (2002). 
24 Walter Sneader, Dep’t of Med. History, The Discovery of Heroin, 352 LANCET 1697, 
1697–98 (1998). 
25 See generally Jana Sawynok, The Therapeutic Use of Heroin: A Review of the 
Pharmacological Literature, 64 CANADIAN J. PHYSIOLOGY & PHARMACOLOGY 1 (1986). 
26 R. Hale-White, Ban on Heroin, 1 BRITISH MED. J. 232, 232 (1956). 
27 Protocol amending the Single Convention on Narcotic Drugs, 1961, supra note 3; 
Single Convention on Narcotic Drugs, supra note 3. 
28 WHO/UNODC/UNAIDS POSITION PAPER: SUBSTITUTION MAINTENANCE THERAPY 
IN THE MANAGEMENT OF OPIOID DEPENDENCE AND HIV/AIDS PREVENTION 13 (2004) 
(Fr.). 
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disease.29 However, methadone does not decrease an individual’s 
physical dependence on opioids, and the goal of methadone 
maintenance therapy (MMT) is to stabilize an opioid user’s life while 
reducing their potential involvement in risky drug-related behaviors.30 
Evidence from randomized controlled trials comparing MMT to no 
opioid replacement therapy suggests that use of methadone within a 
maintenance treatment regime significantly increases the likelihood 
that a heroin-dependent individual will eventually abstain from illicit 
heroin use.31 However, this approach to treating drug dependence 
appears limited in reducing criminality or mortality. 
But the MMT approach has its limitations. In particular, use of 
MMT has been associated with periods (or cycles) of abstention and 
relapse.32 Indeed, research suggests that those heroin users who 
achieve full abstention are in the minority, despite enrollment in 
MMT,33 though it has also been shown that heroin users who 
experience multiple, recurrent MMT treatment episodes are more 
likely to stay in treatment for longer episodes.34 While MMT remains 
a first-line, clinically-proven treatment option for drug-dependent 
individuals, this approach has limited effectiveness at the community 
level. As such, complementary treatment options are needed to 
meaningfully reduce the incidence of drug dependence, injection drug 
use, and HIV transmission resulting from this behavior. 
C. Heroin Prescription 
The limitations of substitution maintenance therapy for opioid 
dependence have led to experimentation with other potential 
approaches to reducing ongoing illicit opioid use. In particular, it has 
been increasingly recognized that, while heroin is highly addictive, 
 
29 A. Thomas McLellan et al., Drug Dependence, a Chronic Medical Illness: 
Implications for Treatment, Insurance, and Outcomes Evaluation, 284 J. AM. MED. ASS’N 
1689, 1689–90 (2000). 
30 RICHARD P. MATTICK ET AL., THE COCKRANE COLLABORATION, METHADONE 
MAINTENANCE THERAPY VERSUS NO OPIOID REPLACEMENT THERAPY FOR OPIOID 
DEPENDENCE 5 (2009). 
31 Id. at 10. 
32 Bohdan Nosyk et al., Proportional Hazards Frailty Models for Recurrent Methadone 
Maintenance Treatment, 170 AM. J. EPIDEMIOLOGY 783, 783 (2009). 
33 See Anja Dobler-Mikola et al., Patterns of Heroin, Cocaine, and Alcohol Abuse 
During Long-Term Methadone Maintenance Treatment, 29 J. SUBSTANCE ABUSE 
TREATMENT 259, 262 (2005). 
34 Nosyk et al., supra note 32, at 787. 
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many of the heroin-related harms that policymakers and clinicians 
have attempted to reduce—HIV transmission via the sharing of 
contaminated needles, fatal overdose, and involvement in acquisitive 
crime—are related to the context in which heroin use occurs, rather 
than with the use of heroin itself.35 Coupled with ongoing resistance 
to MMT among heroin-dependent individuals and suboptimal 
treatment outcomes and retention in maintenance therapies, 
researchers and policymakers have explored the development of 
heroin-based treatments for opioid dependence. 
1. Administration of Heroin-Assisted Treatment (HAT) 
Medically-prescribed heroin-assisted treatment (HAT) is based 
around the provision of heroin to MMT-experienced individuals who 
are dependent on opioids. In randomized controlled trials (RCTs) of 
HAT and in settings where this therapy is prescribed, it is provided 
under strict medical supervision. Specifically, heroin-assisted 
treatment involves the prescription of a regulated dosage of heroin 
(e.g., diacetylmorphine) that is self-administered by those undergoing 
therapy under the strict supervision of medical staff in a controlled, 
sterile environment. In all settings in which HAT has been evaluated 
or implemented, the dosage of heroin is provided as an injectable 
substance, with one exception: clinicians in the Netherlands are given 
the option of prescribing diacetylmorphine base for inhalation rather 
than injection). 
Similarly to MMT, HAT is often described as a harm reduction 
intervention insofar as ongoing drug use is tolerated among clients 
and there is generally no requirement that individuals cease using 
drugs. However, HAT does aim to keep opioid-dependent users in 
treatment, particularly those who have failed in other treatment 
modalities such as MMT. For this reason, HAT is a second-line 
treatment option available only to opiate-dependent individuals who 
have failed conventional substitution treatment (e.g. MMT or 
buprenorphine maintenance treatment).36 
 
35 See DANIEL WOLFE & KASIA MALINOWSKA-SEMPRUCH, OPEN SOC’Y INST., ILLICIT 
DRUG POLICIES AND THE GLOBAL HIV EPIDEMIC: EFFECTS OF UN AND NATIONAL 
GOVERNMENT APPROACHES 2–3 (2004); Tim Rhodes, The ‘Risk Environment’: A 
Framework for Understanding and Reducing Drug-Related Harm, 13 INT’L J. DRUG 
POL’Y 85, 88–89 (2002). 
36 JOHN STRANG ET AL., EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG 
ADDICTION, NEW HEROIN-ASSISTED TREATMENT: RECENT EVIDENCE AND CURRENT 
PRACTICES OF SUPERVISED INJECTABLE HEROIN TREATMENT IN EUROPE AND BEYOND 
11 (2012) (Lux.). 
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Additionally, much like other pharmacotherapies designed to treat 
drug dependence, HAT aims to improve health and social outcomes 
among drug-dependent individuals. These outcomes include a 
reduction in HIV risk behaviors (e.g., used syringe sharing), improved 
physical and mental health, reductions in or abstention from non-
prescribed drug use, reduced criminal recidivism, and improved 
psychosocial adjustment.37 At present, HAT is provided or being 
evaluated in six different countries, including Switzerland,38 the 
Netherlands,39 Germany,40 the United Kingdom,41 Spain,42 and 
Canada.43 HAT is a relatively new or emerging treatment option in all 
of these settings, though non-supervised prescription heroin has been 
available to treat opioid addiction in the United Kingdom since the 
1920s.44 
2. Results of HAT 
A systematic review of HAT published in 2011, restricted to 
randomized controlled trials, identified a positive direction of effect in 
favor of HAT.45 The review identified eight studies comparing 
participants enrolled in HAT with participants enrolled in other 
 
37 See Benedikt Fischer et al., Heroin-Assisted Treatment (HAT) a Decade Later: A 
Brief Update on Science and Politics, 84 J. URB. HEALTH 552, 554–56 (2007). 
38 See, e.g., Thomas V. Perneger et al., Randomised Trial of Heroin Maintenance 
Programme for Addicts Who Fail in Conventional Drug Treatments, 317 BRIT. MED. J. 13 
(1998). 
39 See, e.g., Wim van den Brink et al., Medical Prescription of Heroin to Treatment 
Resistant Heroin Addicts: Two Randomised Controlled Trials, 327 BRIT. MED. J. 310 
(2003). 
40 See, e.g., Franziska Güttinger et al., Evaluating Long-Term Effects of Heroin-
Assisted Treatment: The Results of a 6-Year Follow-Up, 9 EUR. ADDICTION RES. 73 
(2003). 
41 See, e.g., John Strang et al., Supervised Injectable Heroin or Injectable Methadone 
Versus Optimised Oral Methadone as Treatment for Chronic Heroin Addicts in England 
After Persistent Failure in Orthodox Treatment (RIOTT): A Randomised Trial, 375 
LANCET 1885 (2010). 
42 See, e.g., Eugenia Oviedo-Joekes et al., The Andalusian Trial on Heroin-Assisted 
Treatment: A 2 Year Follow-Up, 29 DRUG AND ALCOHOL REVOCABLE TRUST. 75 (2010). 
43 See, e.g., Eugenia Oviedo-Joekes et al., Scientific and Political Challenges in North 
America’s First Randomized Controlled Trial of Heroin-Assisted Treatment for Severe 
Heroin Addiction: Rationale and Design of the NAOMI Study, 6 CLINICAL TRIALS 261 
(2009). 
44 Scientific evaluations of this approach in the United Kingdom have only recently 
been undertaken. Nicky Metrebian & Gerry V. Stimson, Heroin Prescribing in the UK: 
Lost Opportunities for Research, 8 ADDICTION RES. 305, 305–07 (2000). 
45 Id. at 308. 
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maintenance pharmacotherapies such as MMT and buprenorphine 
maintenance treatment.46 All participants were adults who had 
previously failed conventional therapy.47 Six studies found that a 
combination of oral methadone and HAT was more effective than oral 
methadone on its own in reducing illicit drug use.48 Additionally, 
studies included in the review also suggested that HAT has a positive 
impact in reducing levels of criminality and incarceration.49 
However, the authors identified a significantly higher risk 
associated with adverse events related to study medication among 
those enrolled in HAT.50 The authors therefore conclude that HAT is 
an effective pharmacotherapy for treatment-experienced drug users 
that should be provided under medical supervision.51 
A number of observational studies of the effectiveness of HAT 
have also yielded important findings. A recent review undertaken by 
the European Monitoring Centre for Drugs and Drug Addiction noted 
that the majority of studies found that patients enrolled in HAT 
reported abstention from illicit heroin use, though a more common 
outcome was a reduction in the use of illicit heroin.52 Additionally, 
the review found that while retention in treatment varied across 
studies in different settings, there was a marked reduction in criminal 
recidivism across HAT-enrolled participants, particularly when 
compared with participants enrolled in conventional therapy.53 
Longer-term studies on HAT effectiveness, some of which provide up 
to six years of data, have reported patient retention rates in HAT of up 
to 55% after two years54 and 45.8% at six years,55 which compare 
favorably to retention rates among patients enrolled in MMT. 
Finally, those studies that provided cost estimates have consistently 
demonstrated that the direct costs of HAT exceed those of comparable 
pharmacotherapies such as MMT. Indeed, the cost of HAT provision 
in the Netherlands is estimated at €20,400, compared to a cost of 
 
46 MARICA FERRI ET AL., THE COCHRANE COLLABORATION, HEROIN MAINTENANCE 
FOR CHRONIC HEROIN-DEPENDENT INDIVIDUALS 14–15 (2012). 
47 Id. at 3. 
48 Id. at 6, 13–14. 
49 Id. at 13. 
50 Id. at 15. 
51 Id. 
52 See STRANG ET AL., supra note 36, at 12. 
53 Id. at 12. 
54 Uwe Verthein et al., Long-Term Effects of Heroin-Assisted Treatment in Germany, 
103 ADDICTION 960, 962 (2008). 
55 Güttinger et al., supra note 40, at 78. 
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€1,600 associated with the provision of MMT.56 Similarly, the cost of 
HAT in Germany was estimated at €19,000 compared to €3,500 for 
MMT provision.57 These substantially higher costs are the result of 
greater staffing requirements related to the increased potential for 
adverse events associated with HAT. While such costs present a 
challenge, experts have noted that they are likely offset by the indirect 
cost savings from reduced incidence of HIV infection, arrest, and 
incarceration among drug users related to HAT’s increased 
effectiveness compared with other treatment options.58 
III 
POLICY IMPLICATIONS 
These results have wide implications for the development of 
comprehensive approaches to reducing drug-related harms in a variety 
of settings. While still a source of controversy,59 the results of two 
decades of research on HAT demonstrate that it is effective as a 
second-line treatment option for opioid-dependent individuals for 
whom conventional treatment has failed.60 Despite its higher cost 
relative to other standard maintenance therapies, HAT has been found 
to be cost-effective, primarily as a result of its increased impact on 
reducing recidivism.61 
Policymakers have been increasingly concerned with the lack of 
effectiveness of drug law enforcement in reducing levels of drug use 
and drug-related harms.62 Indeed, recent research suggests that 
conventional drug law enforcement approaches likely exacerbate a 
wide range of drug-related harms, including HIV transmission, 
mortality, and drug market violence.63 As a result, certain regions—
 
56 STRANG ET AL., supra note 36, at 13. 
57 Id. 
58 Id. at 13–14. 
59 See Meldon Kahan et al., Why we object to NAOMI: Heroin Maintenance in Canada, 
52 CANADIAN FAMILY PHYSICIAN 705, 705–06 (2006). 
60 FERRI ET AL., supra note 46, at 2–3; STRANG ET AL., supra note 36, at 28–29. 
61 See A. UCHTENHAGEN ET AL., PRESCRIPTION OF NARCOTICS FOR HEROIN ADDICTS: 
MAIN RESULTS OF THE SWISS NATIONAL COHORT STUDY 63–69 (1999) (Switz). 
62 See Degenhardt et al., supra note 4, at 1061–65. 
63 GLOBAL COMM’N ON DRUG POLICY, THE WAR ON DRUGS AND HIV/AIDS, supra 
note 2, at 2; GLOBAL COMM’N ON DRUG POLICY, WAR ON DRUGS: REPORT OF THE 
GLOBAL COMMISSION ON DRUG POLICY 2 (2011); Dan Werb et al., Effect of Drug Law 
Enforcement on Drug Market Violence: A Systematic Review, 22 INT’L J. DRUG POL’Y 87, 
87–88 (2011). 
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most notably Western Europe, Latin America, and certain states in the 
United States—have begun to experiment with novel approaches to 
drug policy.64 Within this policy framework, the focus has 
increasingly shifted from policies aimed at reducing drug use toward 
policies for managing drug-related harms, most notably the risk of 
HIV transmission experienced by IDU.65 At this stage, consensus 
regarding the necessary steps toward evidence-based policy in this 
area has been reached among experts,66 and is reflected in current 
guidelines from relevant UN agencies.67 These guidelines focus on 
the provision of a comprehensive suite of interventions for the 
reduction of HIV and other drug-related harms, including the 
provision of opioid substitution therapy and related addiction 
treatment therapies. In this context, and given its proven 
effectiveness, HAT should be considered alongside this suite of 
interventions by policymakers in settings experiencing severe drug-
related harms. 
It is encouraging in this regard that a number of countries, 
including Switzerland, the Netherlands, Denmark, Germany, and the 
United Kingdom, provide HAT as part of a comprehensive public 
health-oriented drug policy approach. Unfortunately, while trials have 
been completed most recently in Canada and Spain,68 the 
implementation of HAT within a policy framework has yet to 
materialize in these settings, while in Australia, political interference 
forced the early demise of a HAT study.69 These experiences 
exemplify the opposition to HAT, and to harm reduction more 
broadly, that continues to exist in many settings marked by high 
levels of drug-related harm, most notably the United States and 
Russia. Policymakers in Russia have banned methadone and 
 
64 GREENWALD, supra note 16, at 1–2; Illegal Drugs: The Great Experiment: At Last, 
Drug Prohibition is Being Challenged by Fresh Thinking, ECONOMIST (Feb. 23, 2013), 
http://www.economist.com/news/leaders/21572197-last-drug-prohibition-being                  
-challenged-fresh-thinking-great-experiment. 
65 See generally Beyrer et al., supra note 18, at 551–53. 
66 Wood et al., supra note 2, at 310–12. 
67 See generally MARTIN C. DONOGHOE ET AL., WORLD HEALTH ORG., WHO, 
UNODC, UNAIDS TECHNICAL GUIDE FOR COUNTRIES TO SET TARGETS FOR UNIVERSAL 
ACCESS TO HIV PREVENTION, TREATMENT AND CARE FOR INJECTING DRUG USERS 
(2009). 
68 See generally Oviedo-Joekes et al., supra note 42 (Spain); Oviedo-Joekes et al., 
supra note 43 (Canada). 
69 Alex D.Wodak, Public Health and Politics: The Demise of the ACT Heroin Trial, 
167 MED. J. AUSTL. 348, 348–49 (1997). 
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buprenorphine, despite the fact that these are both on the World 
Health Organization’s List of Essential Medicines.70 
While the U.S. government has supported the provision of MMT, it 
is unlikely, given congressional opposition to even basic harm 
reduction services,71 that the suite of interventions supported by the 
federal government will be expanded to include HAT. This is 
unfortunate, given the high prevalence of HIV among American IDU 
populations, and the failure of current policy approaches in reducing 
the incidence of injecting among this marginalized group. 
CONCLUSION 
Two decades of research demonstrates the effectiveness of HAT as 
a secondary treatment option for opioid-dependent individuals who 
have failed in conventional pharmacotherapies such as MMT. Indeed, 
scientific studies from a range of countries, including longitudinal 
studies of up to six years, have demonstrated the utility of HAT in 
achieving a wide range of positive outcomes among clients. Such 
achievements include reductions in HIV risk behaviors and illicit drug 
use, reduced criminal recidivism, and improved mental and physical 
health.72 The direct costs of HAT are greater than those associated 
with other treatment options. However, it is likely that these costs are 
offset by indirect savings related to reductions in HIV transmission or 
the arrest and incarceration of highly dependent individuals that likely 
stem from the provision of HAT. 
As such, experts have called for the expanded provision of this 
clinical treatment option to support a comprehensive set of 
interventions, most notably MMT, to reduce drug-related harms.73 
Despite controversy regarding the provision of harm reduction 
interventions, policymakers should act urgently to provide HAT and 
other clinically- proven treatment options to avert ongoing morbidity 
and mortality arising from untreated drug dependence.74 
 
70 Bertrand Audoin & Chris Beyrer, Russia’s Retrograde Stand on Drug Abuse, N.Y. 
TIMES (Mar. 2, 2012), http://www.nytimes.com/2012/03/03/opinion/russias-retrograde      
-stand-on-drug-abuse.html?pagewanted=all&_r=1&. 
71 Pete Kasperowicz, DC Delegate: Congress has ‘Killed’ with Needle Exchange 
Prohibition, THE HILL (Apr. 5, 2011), http://thehill.com/blogs/floor-action/house/154047  
-holmes-norton-says-congress-has-killed-dc-residents-with-needle-exchange-policy. 
72 FERRI ET AL., supra note 46, at 1–2; Fischer et al., supra note 37, at 554–56. 
73 STRANG ET AL., supra note 36, at 162–64. 
74 Louisa Degenhardt et al., Mortality Among Regular or Dependent Users of Heroin 
and Other Opioids: A Systematic Review and Meta-Analysis of Cohort Studies, 106 
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